Innovations in Tuberculosis Management: Advancements in Drug-Resistant TB Treatment and Rapid Diagnostics

Year : 2025 | Volume : 02 | Issue : 02 | Page :
    By

    Shireen Siddique1,

  • Priyanka Sharma,

  1. Faculty, Department of Pharmacy, Barkatullah University, Bhopal, Madhya Pradesh, India
  2. Student, Department of Pharmacy, Barkatullah University, Bhopal, Madhya Pradesh, India

Abstract

Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, exacerbated by the increasing prevalence of drug-resistant strains, such as multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). Despite advancements in first-line and second-line treatments, resistance to conventional antibiotics has complicated therapeutic strategies, necessitating novel approaches. This mini review explores emerging advancements in TB treatment, including gene editing technologies, such as CRISPR, which offer potential for precise targeting of drug-resistant bacterial strains. Additionally, recent research has uncovered mechanisms underlying bedaquiline’s enhanced efficacy in MDR-TB treatment, revealing metabolic vulnerabilities in resistant strains. Rapid diagnostic tools, including CRISPR-based platforms, have significantly improved TB detection and drug resistance profiling, enabling early and accurate interventions. Moreover, the development of shorter, all-oral regimens, such as the WHO-recommended BPaLM and BPaL regimens, has demonstrated high treatment success rates while reducing toxicity and improving patient adherence. These advancements signify a transformative shift in TB management, paving the way for more effective, patient-friendly, and sustainable treatment strategies.

Keywords: Tuberculosis, drug-resistant TB, CRISPR technology, bedaquiline, rapid diagnostics

[This article belongs to International Journal of Antibiotics ]

How to cite this article:
Shireen Siddique1, Priyanka Sharma. Innovations in Tuberculosis Management: Advancements in Drug-Resistant TB Treatment and Rapid Diagnostics. International Journal of Antibiotics. 2025; 02(02):-.
How to cite this URL:
Shireen Siddique1, Priyanka Sharma. Innovations in Tuberculosis Management: Advancements in Drug-Resistant TB Treatment and Rapid Diagnostics. International Journal of Antibiotics. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijab/article=2025/view=222330


References

  1. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
  2. Padda IS, Muralidhara Reddy K. Antitubercular medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2025 Jul 17]. Available from:https://www.ncbi.nlm.nih.gov/books/NBK557666/.
  1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: WHO; 2010.
  2. Shi J, Su R, Zheng D, Zhu Y, Ma X, Wang S, et al. Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929–41.
  3. Ofori-Anyinam B, Hamblin M, Coldren ML, Li B, Mereddy G, Shaikh M, et al. Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline. Nat Commun. 2024;15(1):9792.
  4. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6(9):a025320.
  5. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029.
  6. Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131–40.
  7. World Health Organization. The End TB Strategy. Geneva: WHO; 2015 [cited 2025 Jul 17]. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19.
  8. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570–81.
  9. Marais BJ, Brittle W, Painczyk K, Hesseling AC, Beyers N, Wasserman E, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis. 2008;47(2):203–7.
  10. Notomi T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):E63.
  11. World Health Organization. The use of loop-mediated isothermal amplification for the diagnosis of TB: policy guidance. Geneva: WHO; 2016 [cited 2025 Jul 17]. Available from:http://www.who.int/tb/features_archive/TB_LAMP/en/.
  1. Global Laboratory Initiative. Practical considerations for implementation of TB-LAMP. Geneva: Stop TB Partnership; 2016 [cited 2025 Jul 17]. Available from:http://www.stoptb.org/wg/gli/assets/documents/.
  1. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48(1):229–37.
  2. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537–44.
  3. Wang L, Yang J, Chen L, Wang W, Yu F, Xiong H. Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance. Epidemiol Infect. 2022;150:e22.
  4. Molbio Diagnostic Product Limited. Truenat™ MTB Plus package insert. 2020 [cited 2025 Jul 17]. Available from:http://www.molbiodiagnostics.com/uploads/product_download/20190927.152146~Truenat-MTB-Plus-packinsert.pdf.
  1. Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5(7):643–56.
  2. Groenen PMA, Bunschoten AE, van Soolingen D, van Embden JD. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol. 1993;10(5):1057–65.
  3. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439–44.
  4. Wang X, Jowsey WJ, Cheung C-Y, Smart CJ, Klaus HR, Seeto NE, et al. Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis. Nat Commun. 2024;15(1):9791.
  5. Ofori-Anyinam B, Hamblin M, Coldren ML, Li B, Mereddy G, Shaikh M, et al. Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline. Nat Commun. 2024;15(1):9792.
  6. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–83.
  7. Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Patter L, et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12(4):326–8.
  8. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23.
  9. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360(6387):436–9.
  10. Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353(6299):aaf5573.
  11. Zein-Eddine R, Refrégier G, Cervantes J, Yokobori NK. The future of CRISPR in Mycobacterium tuberculosis J Biomed Sci. 2023;30(1):34.
  12. Cheung C-Y, McNeil MB, Cook GM. Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis J Antimicrob Chemother. 2022;77(3):615–9.
  13. Sodani M, Misra CS, Rath D, Kulkarni S. Harnessing CRISPR-Cas9 as an anti-mycobacterial system. Microbiol Res. 2023;270:127319.
  14. Press Information Bureau, Government of India. Union Health Ministry approves introduction of new shorter and more efficacious treatment regimen for drug-resistant TB in India [Internet]. 2024 Sep 6 [cited 2025 Jul 17]. Available from: https://pib.gov.in.
  15. World Health Organization. Module 4: Drug-resistant tuberculosis treatment, 2022 update – The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen. WHO TB Knowledge Sharing Platform; 2022 [cited 2025 Jul 17]. Available from:https://tbksp.who.int/en/node/576.
Regular Issue Subscription Review Article
Volume 02
Issue 02
Received 21/02/2025
Accepted 24/03/2025
Published 28/03/2025
Publication Time 35 Days
67

Login


My IP

PlumX Metrics